Bispecific Antibodies are increasingly being explored in combination with other therapies, including immunotherapies, to enhance treatment outcomes. For instance, combining BsAbs with immune checkpoint inhibitors has shown promise in enhancing T-cell activation and overcoming resistance mechanisms in cancer. Furthermore, bispecific antibodies can be used in conjunction with CAR-T cell...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian